TAK-633-4008: Quantitative Testing of Patient and Prescriber Knowledge, Attitudes, and Behavior about GATTEX (Teduglutide) for Injection Safety and Use Information (GATTEX KAB)

Study identification

• EU PAS number:
  EUPAS48716
• Study ID:
  49716
• Official title and acronym:
  TAK-633-4008: Quantitative Testing of Patient and Prescriber Knowledge, Attitudes, and Behavior about GATTEX (Teduglutide) for Injection Safety and Use Information (GATTEX KAB)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The main aim of this study is to check the level of knowledge and assess attitudes and behaviors of both participants and physicians regarding the risks and safe use of GATTEX. The survey will be done via internet, telephone, or paper and both physicians and participants will be able to choose the method that is preferred.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Takeda

Study timelines

Date when funding contract was signed

Actual: 01/08/2013

Study start date

Actual: 01/08/2013

Date of final study report

Planned: 31/12/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Takeda

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only

Other study registration identification numbers and links

NCT05561647 (https://clinicaltrials.gov/ct2/show/NCT05561647),TAK-633-4008 (https://clinicaltrials.takeda.com/study-detail/43674fa3720540ed?idFilter=%5B%22TAK-633-4008%22%5D)